Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in TMO — Thermo Fisher Scientific Inc.

CIK 1423053 MIAMI, FL
Back to TMO Full portfolio

Position in TMO

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$424,922,277
+$24,867,101 QoQ
Shares Held
864,489
+25.2% QoQ
Ownership
0.233%
of shares outstanding
% of Portfolio
0.33%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in TMO Over Time

Shares Held

Position Value (USD)

Derivatives in TMO

reported options exposure · as of Mar 31, 2026
CallValue
$144,313,208
CallShares
293,600
PutValue
$97,126,328
PutShares
197,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Diagnostics & Research

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $1,657,068,556 across 34 Diagnostics & Research names. TMO ranks #1 (25.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 TMO
Thermo Fisher Scientific Inc.
This page 		864,489 $424,922,277
2 CRL
Charles River Laboratories International, Inc.
 1,212,152 $209,096,220
3 A
Agilent Technologies, Inc.
 1,801,714 $205,359,361
4 DHR
Danaher Corp /De/
 1,026,347 $194,595,390
5 MTD
Mettler Toledo International Inc/
 58,054 $73,217,704
6 GH
Guardant Health, Inc.
 775,941 $71,673,669
7 DGX
Quest Diagnostics Inc
 347,218 $68,047,783
8 IQV
Iqvia Holdings Inc.
 390,042 $66,517,762

All Filings in TMO

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $97,126,328 197,600
2026-03-31 $144,313,208 293,600
2026-03-31 $424,922,277 864,489
2025-12-31 $400,055,176 690,405
2025-12-31 $166,533,930 287,400
2025-12-31 $203,792,565 351,700
2025-09-30 $141,916,852 292,600
2025-09-30 $167,137,892 344,600
2025-09-30 $169,611,978 349,701
2025-06-30 $145,803,416 359,600
2025-06-30 $444,717,853 1,096,823
2025-06-30 $121,475,816 299,600
2025-03-31 $59,997,124 120,573
2025-03-31 $67,623,840 135,900
2025-03-31 $141,616,960 284,600
2024-12-31 $137,340,720 264,000
2024-12-31 $176,846,985 339,940
2024-12-31 $125,843,637 241,900
2024-09-30 $192,560,841 311,300
2024-09-30 $160,890,057 260,100
2024-09-30 $102,797,673 166,186
2024-06-30 $543,429,782 982,694
2024-06-30 $130,286,800 235,600
2024-06-30 $141,789,200 256,400
2024-03-31 $200,401,208 344,800
2024-03-31 $138,386,101 238,100
2024-03-31 $58,510,410 100,670
2023-12-31 $148,992,753 280,700
2023-12-31 $280,721,561 528,875
2023-12-31 $232,963,731 438,900
2023-09-30 $171,591,630 339,000
2023-09-30 $125,003,742 246,960
2023-09-30 $238,051,751 470,300
2023-06-30 $65,635,106 125,798
2023-06-30 $292,910,450 561,400
2023-06-30 $218,352,375 418,500
2023-03-31 $244,265,606 423,800
2023-03-31 $204,899,535 355,500
2023-03-31 $137,011,794 237,715
2022-12-31 $83,514,891 151,655
2022-12-31 $229,747,868 417,200
2022-12-31 $232,281,042 421,800
2022-09-30 $419,953,320 828,000
2022-09-30 $15,561,603 30,682
2022-09-30 $228,184,781 449,900
2022-06-30 $148,143,763 272,684
2022-06-30 $189,007,112 347,900
2022-06-30 $217,420,656 400,200
2022-03-31 $392,191,600 664,000
2022-03-31 $224,506,065 380,100

Report a Problem

Category
Description
Email (optional, for follow-up)